Intuitive Surgical, Inc. — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020. The company develops and sells da Vinci surgical systems and the Ion endoluminal system, along with instruments, accessories, and services.
Financial performance and liquidity
| Metric | Q1 2020 | Q1 2019 | Change / context |
|---|---|---|---|
| Total revenue | $1,099.5 million | $973.7 million | Up 13% |
| Product revenue | $900.8 million | $799.8 million | Up 13% |
| Service revenue | $198.7 million | $173.9 million | Up 14% |
| Gross profit / margin | $738.2 million / 67.1% | $669.6 million / 68.8% | Margin down 1.7 percentage points |
| Operating income | $283.0 million | $252.2 million | Up 12%; operating margin approximately 25.7% versus 25.9% |
| Net income attributable to Intuitive | $313.5 million | $306.5 million | Up 2%; diluted EPS $2.62 versus $2.56 |
| Cash from operations | $352.8 million | $333.2 million | Up $19.6 million |
At March 31, cash and cash equivalents were $1.224 billion, with short- and long-term investments of $4.672 billion; combined cash, cash equivalents, and investments totaled approximately $5.9 billion. Total liabilities were $1.361 billion. The balance sheet provided does not show a separate debt balance, so the filing text here does not provide a clear value for debt. Management said existing liquidity and operating cash generation were expected to meet requirements for the foreseeable future, while warning that COVID-19 could reduce operating cash flow and increase inventory needs.
Operating cash flow exceeded net income, supported by noncash charges, including $90.6 million of share-based compensation, $64.5 million of deferred taxes, and $51.1 million of depreciation and disposal losses. Investing cash flow was negative $117.1 million and financing cash flow negative $178.7 million. The company repurchased $100 million of stock and paid $148.9 million for tax withholding on equity awards. Capital expenditures are expected to exceed $400 million in both 2020 and 2021.
Changes versus the prior comparable period
- Da Vinci procedures grew approximately 10% to 309,000, versus approximately 18% growth in Q1 2019. U.S. growth was approximately 9% and outside-U.S. growth approximately 11%.
- Instruments and accessories revenue rose 12% to $617.5 million; systems revenue rose 14% to $283.3 million; service revenue rose 14%.
- The company shipped 237 da Vinci systems, versus 235 a year earlier. Its installed base reached approximately 5,669, up approximately 11% year over year.
- Product gross margin declined, primarily due to da Vinci Si transition costs, higher freight, amortization, and share-based compensation. Service gross margin improved, mainly due to lower repair costs.
- Net income growth was modest despite higher operating income; the reported income tax benefit was $8.1 million, compared with a $24.3 million benefit in Q1 2019. The effective tax rate was 2.6% versus 8.7%, with the difference largely reflecting lower excess tax benefits from employee equity awards.
Outlook, management commentary, and risks
- COVID-19: The filing describes a sharp late-quarter downturn. U.S. procedures per week fell approximately 65% from earlier Q1 levels; China procedures fell approximately 90% in early February before recovering to approximately 70% of early-January weekly levels by quarter-end. Management expected procedures and system placements to decline significantly or be delayed in Q2 and beyond, but could not reliably estimate the duration or magnitude.
- The company withdrew its full-year 2020 financial and procedure guidance because of pandemic uncertainty. Management also expected reduced Q2 demand to leave production facilities below normal capacity, with fixed production overhead and labor costs reducing gross margin.
- Management anticipated continued investment in research and development and expected R&D expense to increase. It also planned to curtail certain spending, pause hiring for volume-related roles, and maintain customer support and supply-chain investment.
- COVID-19 risks include deferred elective surgery, hospital capital-spending cuts, supply-chain and facility disruption, reduced customer access, delayed payments, lease defaults or amended arrangements, and possible recessionary effects on demand. Management expected to extend payment terms in some cases and increase inventory.
- Other material matters include product-liability lawsuits and Ethicon patent disputes, including a U.S. International Trade Commission investigation involving stapler products. An adverse ruling could restrict imports or require product workarounds; the company could not estimate a possible loss range for the disclosed matters. Several product-liability cases had trial dates within the next 12 months.
- The filing also identifies tax uncertainty: gross unrecognized tax benefits were $100.7 million, and a pending appeal concerning intercompany share-based compensation treatment could adversely affect tax expense if resolved against the company.
- In February 2020, Intuitive acquired Orpheus Medical to expand its informatics platform. The company reported $1.501 billion of remaining performance obligations, primarily service-related, generally to be recognized over contract terms.
Most important facts for investors to verify
- Subsequent procedure volumes, system placements, customer cancellations or lease amendments, and the pace of recovery in the U.S., Europe, and China.
- Whether COVID-related underutilization, freight, supply constraints, and inventory growth materially pressure gross margin, cash flow, and working capital.
- Current cash and investment balances, capital spending against the stated expectation of more than $400 million annually in 2020 and 2021, and the company’s debt position; the provided filing text does not clearly state a separate debt balance.
- Developments and potential financial exposure in product-liability and Ethicon patent litigation, for which the company said loss ranges could not be estimated.
- Tax-audit and court developments affecting the $100.7 million of unrecognized tax benefits and the company’s tax treatment of share-based compensation.